Drugs News and Research

RSS

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO (bedaquiline) in the STREAM Study.

6 Nov 2014

Scientists find possible way to halt a common fault in different cancers

SCIENTISTS have found a possible way to halt one of the most common faults in many types of cancer, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Wednesday).

6 Nov 2014

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.

6 Nov 2014

Study: Hot flashes are not adequately managed in patients treated for breast cancer

Hot flushes are one of the most distressing conditions faced by women who have been treated for breast cancer, but they are not being adequately addressed by healthcare professionals and some women consider giving up their post cancer medication to try and stop them, a new study has shown.

6 Nov 2014

Weight-loss surgery minimizes use of medicines in people with obesity

Patients with obesity take significantly fewer medications after weight-loss surgery than their non-surgical counterparts, and end up spending 22.4 percent less on drugs for diabetes and heart disease after four years, according to new research.

6 Nov 2014

Study looks at new diagnostic, treatment approaches to neurological conditions

Despite great advances in understanding how the human brain works, psychiatric conditions, neurodegenerative disorders, and brain injuries are on the rise. Progress in the development of new diagnostic and treatment approaches appears to have stalled. In a special issue of the Cell Press journal Neuron, experts look at the challenges associated with "translational neuroscience," or efforts to bring advances in the lab to the patients who need them.

6 Nov 2014

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

Noonan syndrome is a rare disease that is characterised by a set of pathologies, including heart, facial and skeletal alterations, pulmonary stenosis, short stature, and a greater incidence of haematological problems (mainly juvenile myeloid leukaemia, or childhood leukaemia).

6 Nov 2014

MMIS launches MediSpend Federal solution for life sciences industry

MMIS, creator of The MediSpend Global Compliance Platform, the leading global compliance and transparency solution for the life sciences industry, today announced a new solution, MediSpend Federal to support small to mid-size companies in the life sciences industry.

6 Nov 2014

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

Effects of unhealthy lifestyle persist even after atherosclerosis treatment

Almost everyone knows that improving your eating habits will most likely improve your health. What most people may not know, however, is that the effects of poor eating habits persist long after dietary habits are improved. In a new report appearing in the November 2014 issue of the Journal of Leukocyte Biology, scientists use mice to show that even after successful treatment of atherosclerosis (including lowering of blood cholesterol and a change in dietary habits) the effects of an unhealthy lifestyle still affect the way the immune system functions.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

5 Nov 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

A new study by a Florida State University researcher reveals that a new dietary supplement is superior to calcium and vitamin D when it comes to bone health.

5 Nov 2014

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.

5 Nov 2014

Light-activated diabetes drug: an interview with Dr David Hodson

We've known about chemicals that can be light-activated for about five to ten years now. They’ve mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.

5 Nov 2014

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer hope for breast cancer survivors struggling with cancer-related pain and swelling, and point to ways to enhance muscular strength and body image.

5 Nov 2014

Modern bariatric surgery can cut medications in obesity patients

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.

5 Nov 2014

Drugs News and Research

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Scientists find possible way to halt a common fault in different cancers

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Study: Hot flashes are not adequately managed in patients treated for breast cancer

Weight-loss surgery minimizes use of medicines in people with obesity

Study looks at new diagnostic, treatment approaches to neurological conditions

Researchers develop mouse model that reproduces most typical features of Noonan syndrome

MMIS launches MediSpend Federal solution for life sciences industry

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Effects of unhealthy lifestyle persist even after atherosclerosis treatment

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Hospira launches Paricalcitol Injection

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Light-activated diabetes drug: an interview with Dr David Hodson

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Modern bariatric surgery can cut medications in obesity patients

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News